Spectral Characteristics, In Silico Perspectives, Density Functional Theory (DFT), and Therapeutic Potential of Green-Extracted Phycocyanin from Spirulina
Abstract
:1. Introduction
2. Results and Discussion
2.1. Spectral Study of the PC’s Structure
2.1.1. FTIR Spectrum of PC
2.1.2. NMR Spectra of PC
2.2. In Silico Assessment
2.2.1. Density Functional Theory (DFT) Approach
2.2.2. QSAR Toolbox
In Vivo Rat Metabolism Simulator
Rat Liver S9 Metabolism Simulator
Skin Metabolism Simulator
2.2.3. PreADME/T
2.2.4. SwissADME—Lipinski’Rule of Five
2.2.5. SwissTargetPrediction
3. Materials and Methods
3.1. Extraction of PC
3.2. FTIR Spectroscopy
3.3. NMR Spectroscopy
3.4. In Silico Toxicity Assessment
3.4.1. QSAR Toolbox
3.4.2. PreADME/T
3.4.3. SwissADME
3.4.4. PASS Online Predictions
3.4.5. Theoretical Prediction of Toxicity
3.4.6. DFT Approach
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Patel, A.; Pawar, R.; Mishra, S.; Sonawane, S.; Ghosh, P.K. Kinetic studies on thermal denaturation of C-phycocyanin. Indian J. Biochem. Biophys. 2004, 41, 254–257. [Google Scholar] [PubMed]
- Belay, A.; Ota, Y.; Miyakawa, K.; Shimamatsu, H. Current knowledge on potential health benefits of Spirulina. J. Appl. Phycol. 1993, 5, 235–241. [Google Scholar] [CrossRef]
- Dillon, J.C.; Phuc, A.P.; Dubacq, J.P. Nutritional value of the alga Spirulina. World Rev. Nutr. Diet. 1995, 77, 32–46. [Google Scholar] [CrossRef] [PubMed]
- Glazer, A.N.; Stryer, L. Fluorescent tandem phycobiliprotein conjugates. Biophys. J. 1983, 43, 383–386. [Google Scholar] [CrossRef]
- Soni, R.A.; Sudhakar, K.; Rana, R.S. Spirulina–From growth to nutritional product: A review. Trends Food Sci. Technol. 2017, 69, 157–171. [Google Scholar] [CrossRef]
- Wang, X.-Q.; Li, L.-N.; Chang, W.-R.; Zhang, J.-P.; Gui, L.-L.; Guo, B.-L.; Liang, D.-C. Structure of C-phycocyanin from Spirulina platensis at 2.2 Å resolution: A novel monoclinic crystal form for phycobiliproteins in phycobilisomes. Acta Crystallogr. 2001, D57, 784–792. [Google Scholar] [CrossRef]
- Wang, L.; Qu, Y.; Fu, X.; Zhao, M.; Wang, S.; Sun, L. Isolation, purification and properties of an R-Phycocyanin from the phycobilisomes of a marine red macroalga Polysiphonia urceolata. PLoS ONE 2014, 9, e87833. [Google Scholar] [CrossRef]
- Chen, H.; Qi, H.; Xiong, P. Phycobiliproteins-A Family of Algae-Derived Biliproteins: Productions, Characterization and Pharmaceutical Potentials. Mar. Drugs 2022, 20, 450. [Google Scholar] [CrossRef]
- Vadiraja, B.B.; Gaikwad, N.W.; Madyastha, K.M. Hepatoprotective Effect of C-Phycocyanin: Protection for Carbon Tetrachloride andR-(+)-Pulegone-Mediated Hepatotoxicty in Rats. Biochem. Biophys. Res. Commun. 1998, 249, 428–431. [Google Scholar] [CrossRef]
- Liu, Q.; Huang, Y.; Zhang, R.; Cai, T.; Cai, Y. Medical Application of Spirulina platensis Derived C-Phycocyanin. Hindawi Publ. Corp. Evid. Based Complement. Altern. Med. 2016, 2016, 7803846. [Google Scholar] [CrossRef]
- Bito, T.; Teng, F.; Watanab, F. Bioactive Compounds of Edible Purple Laver Porphyra sp. (Nori). J. Agric. Food Chem. 2017, 65, 10685–10692. [Google Scholar] [CrossRef]
- Yuan, B.; Li, Z.; Shan, H.; Dashnyam, B.; Xu, X.; McClements, D.J.; Zhang, B.; Tan, M.; Wang, Z.; Cao, C. A review of recent strategies to improve the physical stability of phycocyanin. J. Curr. Res. Food Sci. 2022, 5, 2329–2337. [Google Scholar] [CrossRef]
- Liu, Y.-C.; Chang, C.-C.; Matsui, H.; Chao, J.C.-J. C-Phycocyanin and Lycium barbarum Polysaccharides Protect against Aspirin-Induced Inflammation and Apoptosis in Gastric RGM-1 Cells. Nutrients 2022, 14, 5113. [Google Scholar] [CrossRef]
- Tello, P.; Calero, N.; Santos, J.; Trujillo-Cayado, L.A. Development of Avocado and Lemon Oil Emulgels Based on Natural Products: Phycocyanin and Pectin. Pharmaceutics 2023, 15, 2067. [Google Scholar] [CrossRef]
- Rasool, M.; Sabina, E.P.; Lavanya, B. Anti-inflammatory Effect of Spirulina fusiformis on Adjuvant-Induced Arthritis in Mice. Biol. Pharm. Bull. 2006, 29, 2483–2487. [Google Scholar] [CrossRef]
- Deng, R.; Chow, T.-J. Hypolipidemic, Antioxidant and Antiinflammatory Activities of Microalgae Spirulina. Card. Rehabil. 2010, 28, 33–45. [Google Scholar] [CrossRef]
- Hoseini, S.M.; Khosravi-Darani, K.; Mozafari, M.R. Nutritional and medical applications of Spirulina microalgae. Mini-Rev. Med. Chem. 2013, 13, 1231–1237. [Google Scholar] [CrossRef]
- Rodrigues, L.; Morone, J.; Hentschke, G.S.; Vasconcelos, V.; Lopes, G. Anti-Inflammatory Activity of Cyanobacteria Pigment Extracts: Physiological Free Radical Scavenging and Modulation of iNOS and LOX Activity. Mar. Drugs 2024, 22, 131. [Google Scholar] [CrossRef]
- Fernández-Rojas, B.; Hernández-Juárez, J.; Pedraza-Chaverri, J. Nutraceutical properties of phycocyanin. J. Funct. Foods 2014, 11, 375–392. [Google Scholar] [CrossRef]
- Abd El-Baky, H.H.; El Baz, F.K.; El-Baroty, G.S. Enhancement of anti-oxidant production in Spirulina platensis under oxidative stress. Acta Physiol. Plant. 2009, 31, 623–631. [Google Scholar] [CrossRef]
- Jenkins, D.J.A.; Kitts, D.; Giovannucci, E.L.; Sahye-Pudaruth, S.; Paquette, M.; Blanco Mejia, S.; Patel, D.; Kavanagh, M.; Tsirakis, T.; Kendall, C.W.C.; et al. Selenium, antioxidants, cardiovascular disease, and all-cause mortality: A systematic review and meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 2020, 112, 1642–1652. [Google Scholar] [CrossRef]
- López-Otín, C.; Blasco, M.A.; Partridge, L.; Serrano, M.; Kroemer, G. The hallmarks of aging. Cell 2013, 153, 1194–1217. [Google Scholar] [CrossRef]
- Upasani, C.D.; Balaraman, R. Protective effect of Spirulina on lead induced deleterious changes in the lipid peroxidation and endogenous antioxidants in rats. Phytother. Res. PTR 2003, 17, 330–334. [Google Scholar] [CrossRef]
- Kalafati, M.; Jamurtas, A.Z.; Nikolaidis, M.G.; Paschalis, V.; Theodorou, A.A.; Sakel-lariou, G.K.; Koutedakis, Y.; Kouretas, D. Ergogenic and antioxidant effects of spirulina supplementation in humans. Med. Sci. Sports Exerc. 2010, 42, 142–151. [Google Scholar] [CrossRef] [PubMed]
- Abdel-Daim, M.M.; Abuzead, S.M.M.; Halawa, S.M. Protective Role of Spirulina platensis against Acute Deltamethrin-Induced Toxicity in Rats. PLoS ONE 2013, 8, e72991. [Google Scholar] [CrossRef]
- Ismail, M.; Hossain, M.F.; Tanu, A.R.; Shekhar, H.U. Effect of spirulina intervention on oxidative stress, antioxidant status, and lipid profile in chronic obstructive pulmonary disease patients. BioMed Res. Int. 2015, 2015, 486120. [Google Scholar] [CrossRef]
- Wu, Q.; Liu, L.; Miron, A.; Klímová, B.; Wan, D.; Kuča, K. The antioxidant, immunomodulatory, and anti-inflammatory activities of Spirulina: An overview. Arch. Toxicol. 2016, 90, 1817–1840. [Google Scholar] [CrossRef] [PubMed]
- Koníčková, R.; Vaňková, K.; Vaníková, J.; Vánová, K.; Muchová, L.; Subhanová, I.; Zadinová, M.; Zelenka, J.; Dvořák, A.; Kolář, M.; et al. Anti-cancer effects of blue-green alga Spirulina platensis, a natural source of bilirubin-like tetrapyrrolic compounds. Ann. Hepatol. 2014, 13, 273–283. [Google Scholar] [CrossRef] [PubMed]
- Romay, C.; González, R.; Ledón, N.; Remirez, D.; Rimbau, V. C-phycocyanin: A biliprotein with antioxidant, anti-inflammatory and neuroprotective effects. Curr. Protein Pept. Sci. 2003, 4, 207–216. [Google Scholar] [CrossRef]
- Grover, P.; Bhatnagar, A.; Kumari, N.; Bhatt, A.N.; Nishad, D.K.; Purkayastha, J. C-Phycocyanin-a novel protein from Spirulina platensis-In vivo toxicity, antioxidant and immunomodulatory studies. Saudi J. Biol. Sci. 2021, 28, 1853–1859. [Google Scholar] [CrossRef]
- Kneip, C.; Parbel, A.; Foerstendorf, H.; Scheer, H.; Siebert, F.; Hildebrandt, P. Fourier transform near-infrared resonance Raman spectroscopic study of the α-subunit of phycoerythrocyanin and phycocyanin from the cyanobacterium Mastigocladus laminosus. J. Raman Spectrosc. 1998, 29, 939–944. [Google Scholar] [CrossRef]
- Szalontai, B.; Gombos, Z.; Csizmadia, V.; Bagyinka, C.; Lutz, M. Structure and interactions of phycocyanobilin chromophores in phycocyanin and allophycocyanin from an analysis of their resonance Raman spectra. Biochemistry 1994, 33, 11823–11832. [Google Scholar] [CrossRef] [PubMed]
- Qiao, B.W.; Liu, X.T.; Wang, C.X.; Song, S.; Ai, C.Q.; Fu, Y.H. Preparation, characterization, and antioxidant properties of phycocyanin complexes based on sodium alginate and lysozyme. Front. Nutr. 2022, 9, 890942. [Google Scholar] [CrossRef]
- Tzaneva, D.; Simitchiev, A.; Petkova, N.; Nenov, V.; Stoyanova, A.; Denev, P. Synthesis of carboxymethyl chitosan and its rheological behaviour in pharmaceutical and cosmetic emulsions. J. Appl. Pharm. Sci. 2017, 7, 70–78. [Google Scholar] [CrossRef]
- Murdzheva, D.; Vasileva, I.; Petkova, N.; Ivanov, I.; Todorova, M.; Denev, P. Physicochemical properties of new alginic acids derivatives. Ind. Technol. 2016, 3, 59–66. [Google Scholar]
- Suresh, M.; Mishra, S.K.; Mishra, S.; Das, A. The detection of Hg2+ by cyanobacteria in aqueous media. Chem. Commun. 2009, 18, 2496–2498. [Google Scholar] [CrossRef]
- Al-Malki, A.L. In vitro cytotoxicity and pro-apoptotic activity of phycocyanin nanoparticles from Ulva lactuca (Chlorophyta) algae. Saudi J. Biol. Sci. 2020, 27, 894–898. [Google Scholar] [CrossRef]
- Garcia-Pliego, E.; Franco-Colin, M.; Rojas-Franco, P.; Blas-Valdivia, V.; Serrano-Contreras, J.I.; Pentón-Rol, G.; Cano-Europa, E. Phycocyanobilin is the molecule responsible for the nephroprotective action of phycocyanin in acute kidney injury caused by mercury. Food Funct. 2021, 12, 2985–2994. [Google Scholar] [CrossRef]
- Song, C.; Matysik, J.; Mark, F. Crystal Effects on Mesobilirubin: A Combined NMR Spectroscopic and Density Functional Theory Study. Photochem. Photobiol. 2017, 93, 834–843. [Google Scholar] [CrossRef]
- Van Thor, J.J.; Mackeen, M.; Kuprov, I.; Dwek, R.A.; Wormald, M.R. Chromophore Structure in the Photocycle of the Cyanobacterial Phytochrome Cph1. Biophys. J. 2006, 91, 1811–1822. [Google Scholar] [CrossRef]
- Daina, A.; Michielin, O.; Zoete, V. SwissADME: A Free Web Tool to Evaluate Pharmacokinetics, Drug-Likeness and Medicinal Chemistry Friendliness of Small Molecules. Sci. Rep. 2017, 7, 42717. [Google Scholar] [CrossRef]
- (ECHA), Quantitative Structure-Activity Relationship Toolbox v4.6. 2023. Available online: https://qsartoolbox.org/ (accessed on 28 March 2024).
- Chengteh, L.; Yang, W.; Parr, R.G. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. Phys. Rev. 1988, B 37, 785. [Google Scholar]
- Krishnan, R.; Binkley, J.S.; Seeger, R.; Pople, J.A. Pople. Self-consistent molecular orbital methods. 20. Basis set for correlated wave-functions. J. Chem. Phys. 1980, 72, 650–654. [Google Scholar] [CrossRef]
- Abu-Dief, A.M.; Omran, A.O.; Feizi-Dehnayebi, M.; Alqurashi, A.; Omar, I.; Alhashmialameer, D.; Mohamad, A.D.M. Fabrication, structural elucidation, and DFT calculation of some new hydrophilic metal chelates based on NN′-(1-methyl-2-oxoindolin-3-ylidene) ben-zohydrazide ligand: Pharmaceutical studies and molecular docking approach. Appl. Organomet. Chem. 2024, 38, e7593. [Google Scholar] [CrossRef]
- Akbari, Z.; Stagno, C.; Iraci, N.; Efferth, T.; Omer, E.A.; Piperno, A.; Montazerozohori, M.; Feizi-Dehnayebi, M.; Micale, N. Biological evaluation, DFT, MEP, HOMO-LUMO analysis and ensemble docking studies of Zn (II) complexes of bidentate and tetradentate Schiff base ligands as antileukemia agents. J. Mol. Struct. 2024, 1301, 137400. [Google Scholar] [CrossRef]
- Rossi, A.; Stagno, C.; Piperno, A.; Iraci, N.; Panseri, S.; Montesi, M.; Feizi-Dehnayebi, M.; Bassi, G.; Letizia Di Pietro, M.; Micale, N. Anticancer activity and morphological analysis of Pt (II) complexes: Their DFT approach, docking simulation, and ADME-Tox profiling. Appl. Organomet. Chem. 2024, 38, e7403. [Google Scholar] [CrossRef]
- Lanez, T.; Feizi-Dehnayebi, M.; Lanez, E. Assessment of the electrostatic binding of ferrocenylmethyl-nitroaniline derivatives to DNA: A combined experimental and theoretical study. J. Mol. Struct. 2024, 1308, 138386. [Google Scholar] [CrossRef]
- Asath, R.M.; Premkumar, R.; Mathavan, T.; Benial, A.M.F. Structural, spectroscopic and molecular docking studies on 2-amino-3-chloro-5-trifluoromethyl pyridine: A potential bioactive agent. Spectrochim. Acta Part. A Mol. Biomol. Spectrosc. 2017, 175, 51–60. [Google Scholar] [CrossRef]
- Qasem, H.A.; Sayed, F.N.; Feizi-Dehnayebi, M.; Al-Ghamdi, K.; Omar, I.; Mohamed, G.G.; Abu-Dief, A.M. Development of tripodal imine metal chelates: Synthesis, physicochemical inspection, theoretical studies and biomedical evaluation. Inorg. Chem. Commun. 2024, 162, 112248. [Google Scholar] [CrossRef]
- Rupa, S.A.; Moni, R.; Patwary, A.; Mahmud, M.; Haque, A.; Uddin, J.; Abedin, S.M. Synthesis of Novel Tritopic Hydrazone Ligands: Spectroscopy, Biological Activity, DFT, and Molecular Docking Studies. Molecules 2022, 27, 1656. [Google Scholar] [CrossRef]
- Abu-Dief, A.M.; El-Dabea, T.; El-Khatib, R.M.; Feizi-Dehnayebi, M.; Aljohani, F.S.; Al-Ghamdi, K.; Barnawi, I.O.; Remaily, A.M.A. Synthesize, structural inspection, stoichiometry in solution and DFT calculation of some novel mixed ligand complexes: DNA binding, biomedical applications and molecular docking approach. J. Mol. Liq. 2024, 399, 124422. [Google Scholar] [CrossRef]
- Milusheva, M.; Gledacheva, V.; Stefanova, I.; Feizi-Dehnayebi, M.; Mihaylova, R.; Nedialkov, P.; Cherneva, E.; Tumbarski, Y.; Tsoneva, S.; Todorova, M.; et al. Synthesis, Molecular Docking, and Biological Evaluation of Novel Anthranilic Acid Hybrid and Its Diamides as Antispasmodics. Int. J. Mol. Sci. 2023, 24, 13855. [Google Scholar] [CrossRef]
- Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46, 3–26. [Google Scholar] [CrossRef]
- Martin, Y.C. A bioavailability score. J. Med. Chem. 2005, 48, 3164–3170. [Google Scholar] [CrossRef]
- Nikolova, K.; Petkova, N.; Mihaylova, D.; Gentscheva, G.; Gavrailov, G.; Pehlivanov, I.; Andonova, V. Extraction of Phycocyanin and Chlorophyll from Spirulina by “Green Methods”. Separations 2024, 11, 57. [Google Scholar] [CrossRef]
- Consortium, T.P. PreADME/T. Available online: https://preadmet.qsarhub.com/adme/ (accessed on 17 April 2024).
- Lipinski, C.A. Lead- and Drug-like Compounds: The Rule-of-Five Revolution. Drug Discov. Today Technol. 2004, 1, 337–341. [Google Scholar] [CrossRef]
- Anzali, S.; Barnickel, G.; Cezanne, B.; Krug, M.; Filimonov, D.; Poroikov, V. Discriminating between Drugs and Nondrugs by Prediction of Activity Spectra for Substances (PASS). J. Med. Chem. 2001, 44, 2432–2437. [Google Scholar] [CrossRef] [PubMed]
- Mathew, B.; Suresh, J.; Anbazhagan, S. Synthesis and PASS-Assisted in Silico Approach of Some Novel 2-Substituted Benzimidazole Bearing a Pyrimidine-2, 4, 6(Trione) System as Mucomembranous Protector. J. Pharm. Bioallied Sci. 2013, 5, 39–43. [Google Scholar] [CrossRef]
- Ottaviani, G.; Gosling, D.J.; Patissier, C.; Rodde, S.; Zhou, L.; Faller, B. What Is Modulating Solubility in Simulated Intestinal Fluids? Eur. J. Pharm. Sci. 2010, 41, 452–457. [Google Scholar] [CrossRef]
- Hollenberg, P.F. Characteristics and Common Properties of Inhibitors, Inducers, and Activators of CYP Enzymes. Drug Metab. Rev. 2002, 34, 17–35. [Google Scholar] [CrossRef]
- Frisch, M.; Trucks, G.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. Gaussian 09, Revision d. 01; Gaussian, Inc.: Wallingford, CT, USA, 2009; p. 201. [Google Scholar]
- Milusheva, M.; Todorova, M.; Gledacheva, V.; Stefanova, I.; Feizi-Dehnayebi, M.; Pencheva, M.; Nedialkov, P.; Tumbarski, Y.; Yanakieva, V.; Tsoneva, S.; et al. Novel Anthranilic Acid Hybrids—An Alternative Weapon against Inflammatory Diseases. Pharmaceuticals 2023, 16, 1660. [Google Scholar] [CrossRef]
Tool | Basic Concept | Type of Information Provided | Reason for Selection |
---|---|---|---|
QSAR Toolbox | A comprehensive tool for predicting the toxicity and metabolism of chemicals using various profilers and simulators. | Predictions of metabolic pathways, toxicity, protein and DNA interactions. | Integrates multiple profilers to provide a holistic view of a compound’s safety profile, including metabolism and toxicity. |
PreADME/T | Focuses on predicting pharmacokinetic properties such as absorption, distribution, metabolism and excretion (ADME). | Pharmacokinetic parameters: intestinal absorption, plasma protein binding, BBB penetration, CYP inhibition, excretion, toxicity. | Provides insights into a compound’s ADME properties, critical for assessing bioavailability and potential drug interactions. |
SwissADME | Analyzes drug-likeness based on Lipinski’s Rule of Five and other parameters; evaluates absorption, distribution, metabolism and excretion (ADME) and predicts the probability of the tested compound to bind to targets. | Drug-likeness parameters: molecular weight, lipophilicity (iLOGP), hydrogen bond donors/acceptors, TPSA, solubility. Target Prediction: likelihood of interaction with specific biological targets. | Assesses a compound’s suitability as a drug based on established pharmacokinetic and drug-likeness rules. Additionally, provides insights into potential biological targets, helping to understand the compound’s broader pharmacological effects. |
Tool | Basic Concept | Type of Information Provided | Reason for Selection |
---|---|---|---|
In vivo Rat Metabolism Simulator | Simulates metabolic processes in rats using 565 biotransformation reactions, includes phase I and II transformations. | Predictions of metabolic pathways and potential activation reactions. | Represents in vivo-like metabolism; crucial for understanding potential metabolic activation of xenobiotics. |
Rat liver S9 Metabolism Simulator | Simulates liver-specific metabolism using a set of 565 biotransformation reactions from rodent liver microsomes and S9 fraction. | Prediction of liver metabolites and associated metabolic pathways. | Provides insights into liver metabolism and potential in vitro genotoxic effects. |
Skin Metabolism Simulator | Simulates metabolism in the skin, including both rate-determining and non-rate-determining transformations. | Predictions of skin metabolites and their potential transformations. | Essential for evaluating dermal exposure and safety, given the differences between skin and liver metabolism. |
DNA Binding by OASIS | Based on the Ames Mutagenicity model, it evaluates chemical structures for 117 structural alerts related to DNA interaction. | Identification of structural alerts and mechanistic domains related to DNA binding. | Focuses on predicting DNA mutagenicity; critical for assessing potential genotoxicity. |
Protein Binding by OASIS | Analyzes chemical structures to identify potential interactions with proteins based on 112 structural alerts and 11 mechanistic domains. | Identification of structural and mechanistic alerts related to protein binding. | Provides comprehensive protein-binding alerts developed by industry consortia; essential for assessing potential protein interactions. |
Structure and Metabolite Number | |
---|---|
1 | 2 |
3 | 4 |
Structure and Metabolite Number | |
---|---|
1 | 2 |
Structure and Metabolite Number | |
---|---|
1 | 2 |
3 | 4 |
5 | 6 |
7 | 8 |
Metabolite Number | Structural Alert | Mechanistic Alert | Mechanistic Domain |
---|---|---|---|
1, 3, 5, 7 | No alert found | - | - |
2, 4, 6, 8 | Epoxides, aziridines, thiiranes, and oxetanes | Alkylation, direct-acting epoxides and related | SN2 |
Metabolite Number | Structural Alert | Mechanistic Alert | Mechanistic Domain |
---|---|---|---|
1–5, 7 | No alert found | - | - |
6, 8 | Epoxides, aziridines, and sulfuranes | Ring opening SN2 reaction | SN2 |
PreADME/Tox Parameters | ||||
---|---|---|---|---|
Absorbtion | ||||
Human Intestinal Absorption | Caco-2 | Skin Permeability | ||
84.638039 | 20.3983 nm/s | −3.80287 logKp, cm/h | ||
Distribution | ||||
Plasma Protein Binding | Blood–Brain Barrier | |||
87.494840 | 0.19048 | |||
Metabolism | ||||
CYP2C19 | CYP2C9 | CYP2D6 | CYP3A4 | |
- | Inhibitor | - | Inhibitor/Substrate | |
Excretion | ||||
MDCK | ||||
0.0434166 nm/s | ||||
Toxicity | ||||
Ames Test | Carcinogenicity Mouse | Carcinogenicity Rat | ||
Mutagen | Negative | Positive |
Target | Common Name | Target Class | Probability |
---|---|---|---|
Integrin alpha-4/beta-1 | ITGB1 ITGA4 | Membrane receptor | 0.06613 |
Integrin alpha-4/beta-7 | ITGB7 ITGA4 | Membrane receptor | 0.06613 |
Integrin alpha-V/beta-3 | ITGAV ITGB3 | Membrane receptor | 0.06613 |
Integrin alpha-IIb/beta-3 | ITGA2B ITGB3 | Membrane receptor | 0.06613 |
Arachidonate 5-lipoxygenase | ALOX5 | Oxidoreductase | 0.06613 |
Prostaglandin E synthase | PTGES | Enzyme | 0.06613 |
FK506-binding protein 1A | FKBP1A | Isomerase | 0.06613 |
Neprilysin (by homology) | MME | Protease | 0.06613 |
Purinergic receptor P2Y12 | P2RY12 | Family A G proteincoupled receptor | 0.06613 |
Endothelin receptor ET-A | EDNRA | Family A G proteincoupled receptor | 0.06613 |
Tyrosine-protein kinase LCK | LCK | Kinase | 0.06613 |
Glutamate carboxypeptidase II | FOLH1 | Protease | 0.06613 |
TNF-alpha | TNF | Secreted protein | 0.06613 |
Phospholipase A2 group 1VB | PLA2G4B | Enzyme | 0.06613 |
Cholecystokinin B receptor | CCKBR | Family A G proteincoupled receptor | 0.06613 |
Protein-tyrosine phosphatase 1B | PTPN1 | Phosphatase | 0.06613 |
T-cell proteintyrosine phosphatase | PTPN2 | Phosphatase | 0.06613 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Andonova, V.; Nikolova, K.; Iliev, I.; Georgieva, S.; Petkova, N.; Feizi-Dehnayebi, M.; Nikolova, S.; Gerasimova, A. Spectral Characteristics, In Silico Perspectives, Density Functional Theory (DFT), and Therapeutic Potential of Green-Extracted Phycocyanin from Spirulina. Int. J. Mol. Sci. 2024, 25, 9170. https://doi.org/10.3390/ijms25179170
Andonova V, Nikolova K, Iliev I, Georgieva S, Petkova N, Feizi-Dehnayebi M, Nikolova S, Gerasimova A. Spectral Characteristics, In Silico Perspectives, Density Functional Theory (DFT), and Therapeutic Potential of Green-Extracted Phycocyanin from Spirulina. International Journal of Molecular Sciences. 2024; 25(17):9170. https://doi.org/10.3390/ijms25179170
Chicago/Turabian StyleAndonova, Velichka, Krastena Nikolova, Ivelin Iliev, Svetlana Georgieva, Nadezhda Petkova, Mehran Feizi-Dehnayebi, Stoyanka Nikolova, and Anelia Gerasimova. 2024. "Spectral Characteristics, In Silico Perspectives, Density Functional Theory (DFT), and Therapeutic Potential of Green-Extracted Phycocyanin from Spirulina" International Journal of Molecular Sciences 25, no. 17: 9170. https://doi.org/10.3390/ijms25179170